Trial Profile
Phase 1 study to evaluate the safety of dasatinib in relapsed and refractory angioimmunoblastic T-cell lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications T-cell lymphoma
- Focus Adverse reactions
- 31 Jul 2018 Status changed from not yet recruiting to completed.
- 31 Jan 2017 New trial record